Long-term follow-Up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease

Human Gene Therapy

Volumn 24, Issue 2, 2013, Pages 203-208

  Rosengart, Todd K ^a   Bishawi, Muath M ^a   Halbreiner, Michael S ^a   Fakhoury, Mathew ^a   Finnin, Eileen ^a   Hollmann, Charleen ^b   Shroyer, Annie Laurie ^a   Crystal, Ronald G ^b  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; VASCULOTROPIN 121;

ADJUVANT THERAPY; ADULT; AGED; ANGINA PECTORIS; ANGIOGENIC GENE THERAPY; ARTICLE; BIOSAFETY; BREAST CANCER; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COLON CANCER; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART MUSCLE ISCHEMIA; HUMAN; MALE; MINIMALLY INVASIVE CARDIAC SURGERY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; RETINOPATHY; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; THORACOTOMY;

ADENOVIRIDAE; AGED; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DNA, COMPLEMENTARY; FEMALE; FOLLOW-UP STUDIES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; THORACOTOMY; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874096269     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.137     Document Type: Article

References (28)

1. Allen, K.B., Dowling, R.D., Angell, W.W., et al. (2004). Transmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trial. Ann. Thorac. Surg. 77, 1228-1234.
2. Altekruse, S.F., Kosary, C.L., Krapcho, M., et al. (2012). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975-2007/
3. Carmeliet, P. (2003). Angiogenesis in health and disease. Nat. Med. 9, 653-660.
4. Cheng, D., Diegeler, A., Allen, K., et al. (2006). Transmyocardial laser revascularization: A meta-analysis and systematic review of controlled trials. Innovations. (Phila) 1, 295-313.
5. Crystal, R.G., Harvey, B.G., Wisnivesky, J.P., et al. (2002). Analysis of risk factors for local delivery of low-and intermediatedose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum. Gene Ther. 13, 65-100.
6. Crystal, R.G., Kaminsky, S.M., Hackett, N.R., et al. (2012). Double-blinded, placebo-controlled, randomized gene therapy using surgery for vector delivery. Hum. Gene Ther. 23, 438-441.
7. Finniss, D.G., Kaptchuk, T.J., Miller, F., et al. (2010). Biological, clinical, and ethical advances of placebo effects. Lancet 375, 686-695.
8. Freedman, S.B., and Isner, J.M. (2002). Therapeutic angiogenesis for coronary artery disease. Ann. Intern. Med. 136, 54-71.
9. Gupta, R., Tongers, J., and Losordo, D.W. (2009). Human studies of angiogenic gene therapy. Circ. Res. 105, 724-736.
10. Hedman, M., Hartikainen, J., Syvanne, M., et al. (2003). Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107, 2677-2683.
11. Hedman, M., Muona, K., Hedman, A., et al. (2009). Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther. 16, 629-634.
12. Horvath, K.A., Aranki, S.F., Cohn, L.H., et al. (2001). Sustained angina relief 5 years after transmyocardial laser revascularization with a CO2 laser. Circulation 104, I81-I84.
13. Kastrup, J., Jorgensen, E., Ruck, A., et al. (2005). Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: A randomized double-blind placebo-controlled study: The Euroinject One trial. J. Am. Coll. Cardiol. 45, 982-988.
14. Laham, R.J., Sellke, F.W., Edelman, E.R., et al. (1999). Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 100, 1865-1871.
15. Lee, L.Y., Patel, S.R., Hackett, N.R., et al. (2000). Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann. Thorac. Surg. 69, 14-23.
16. Losordo, D.W., Vale, P.R., Hendel, R.C., et al. (2002). Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105, 2012-2018.
17. Mitsos, S., Katsanos, K., Koletsis, E., et al. (2012). Therapeutic angiogenesis for myocardial ischemia revisited: Basic biological concepts and focus on latest clinical trials. Angiogenesis 15, 1-22.
18. Patel, S.R., Lee, L.Y., Mack, C.A., et al. (1999). Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121. Hum. Gene Ther. 10, 1331-1348.
19. Rosengart, T.K., Lee, L.Y., Patel, S.R., et al. (1999a). Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann. Surg. 230, 466-470.
20. Rosengart, T.K., Lee, L.Y., Patel, S.R., et al. (1999b). Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100, 468-474.
21. Rosengart, T.K., Patel, S.R., and Crystal, R.G. (1999c). Therapeutic angiogenesis: Protein and gene therapy delivery strategies. J. Cardiovasc. Risk 6, 29-40.
22. Sarkar, N., Ruck, A., Kallner, G., et al. (2001). Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease-12-month follow-up: Angiogenic gene therapy. J. Intern. Med. 250, 373-381.
23. Schumacher, B., Pecher, P., von Specht, B.U., et al. (1998). Induction of neoangiogenesis in ischemic myocardium by human growth factors: First clinical results of a new treatment of coronary heart disease. Circulation 97, 645-650.
24. Simons, M., Bonow, R.O., Chronos, N.A., et al. (2000). Clinical trials in coronary angiogenesis: Issues, problems, consensus: An expert panel summary. Circulation 102, E73-E86.
25. Stewart, D.J., Hilton, J.D., Arnold, J.M., et al. (2006). Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: A phase 2 randomized, controlled trial of Ad-VEGF121 (AdVEGF121) versus maximum medical treatment. Gene Ther. 13, 1503-1511.
26. Symes, J.F., Losordo, D.W., Vale, P.R., et al. (1999). Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann. Thorac. Surg. 68, 830-836.
27. Vale, P.R., Losordo, D.W., Milliken, C.E., et al. (2000). Left ventricular electromechanical mapping to assess efficacy of phVEGF165 gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 102, 965-974.
28. Yang, Z.J., Zhang, Y.R., Chen, B., et al. (2009). Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease. Mol. Biol. Rep. 36, 1323-1329.